Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

Nature Medicine

Volumn 4, Issue 11, 1998, Pages 1302-1307

  Kilby, J Michael ^a   Hopkins, Sam ^b   Venetta, Thomas M ^b   Dimassimo, Betty ^b   Cloud, Gretchen A ^a   Lee, Jeannette Y ^a   Alldredge, Leslie ^a   Hunter, Eric ^c   Lambert, Dennis ^b   Bolognesi, Dani ^d   Matthews, Thomas ^d   Johnson, M Ross ^b   Nowak, Martin A ^e   Shaw, George M ^f   Saag, Michael S ^a  

^a University of Alabama at Birmingham   (United States)

^b Trimeris Inc   (United States)

^c University of Alabama at Birmingham   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e PRINCETON UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENFUVIRTIDE; GLYCOPROTEIN GP 41; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; MEMBRANE FUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; METABOLIC CLEARANCE RATE; PEPTIDE FRAGMENTS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031729823     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/3293     Document Type: Article

References (49)

1. Carpenter, C.C. et al. Anti-retroviral therapy for HIV infection in 1998. J. Am. Med. Assoc. 280, 78-86 (1998).
2. Eron, J.J. et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333, 1662-9 (1995).
3. Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534-9 (1995).
4. Hammer, S. et al. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogs in HIV-infected persons with CD4 cell counts less than or equal to 200 per cubic millimeter. N. Engl. J. Med. 337, 725 (1997).
5. Saag, M.S. Nucleoside analogs: adverse effects. Hosp. Pract. 27 (supp), 26-36 (1992).
6. McDonald, C.K. & Kuritzkes, D.R. HIV-1 protease inhibitors. Arch. Intern. Med. 157, 951-959 (1997).
7. Richman, D.D. Resistance of clinical isolates of HIV to anti-retroviral agents. Antimicrob. Agents Chemother. 37, 1207-1213 (1993).
8. Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-71 (1995).
9. Kwong, P.D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
10. Chan, D.C., Fass, D., Berger, J.M. & Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-73 (1997).
11. Gallaher, W., Ball, J., Garry, R., Griffin, M. & Montelaro R. A general model of the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 5, 431-40 (1989).
12. Delwart, E., Mosialos, G. & Gilmore, T. Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res. Hum. Retroviruses 6, 703-6 (1989).
13. Chen, C.H., Matthews, T., McDanal, C., Bolognesi, D. & Greenberg M. A molecular clasp in HIV-1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Virol. 69, 3771-7 (1995).
14. Lawless, M.K. et al. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 35, 13697-708 (1996).
15. Matthews, T. et al. Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol. Rev. 140, 93-104 (1994).
16. Wild, C., Greenwell, T., Shugars, D., Rimsky-Clarke & Matthews T. The inhibitory activity of an HIV-1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses 11, 323-5 (1995).
17. Wild C., Oas T., McDanal C., Bolognesi D. & Matthews T. A synthetic peptide inhibitor of HIV replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89, 10537-41 (1992).
18. Tan, K., Liu, J.H., Want, J.H., Shen, S., & Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94, 12303-308 (1997).
19. Weissenhorn, W.A., Dessen, A., Harrison, S.C., Skehel, J.J. & Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-30 (1997).
20. Dubay, J., Roberts, S., Brody, B. & Hunter, E. Mutations in the leucine zipper of HIV-1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. 66, 4748-56 (1992).
21. Wild, C. et al. Propensity for a leucine zipper-like domain of HIV-1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA 91, 12676-80 (1994).
22. Bullough, P.A., Hughson, M., Skehel, J.J. & Wiley, D.C. Structure of influena haemagglutinin at the pH of membrane fusion. J. Virol. 371, 37-43 (1994).
23. Carr, C. & Kim, P.S. A spring-loaded mechanism for the conformational change of influenza hemaglutinin. Cell 73, 823-32 (1993).
24. Wild, C., Greenwell, T. & Matthews, T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9, 1051-3 (letter) (1993).
25. Wild, C.T., Shugars, D.C., Greenwell, T.K., McDanal, C.B. & Matthews, T.J. Peptides corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91, 9770-4 (1994).
26. Rimsky, L.T., Shugars, D.C. & Matthews, T. Determinants of HIV-1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-992 (1998).
27. Wei, X, et al. Viral dynamics in HIV-1 infection. Nature 373, 117-22 (1995).
28. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-26 (1995).
29. Herz, A.V.M., Bonhoeffer, S., Anderson, R.M., May, R.M. & Nowak, M.A. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc. Natl. Acad. Sci. USA 93, 7247-51 (1996).
30. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-86 (1996).
31. Montaner, J.S.G. et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. J. Am. Med. Assoc. 279, 930-37 (1998).
32. Nowak, M.A., Bonhoeffer, S., Shaw, G.M. & May, R.M. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184, 203-17 (1997).
33. Bonhoeffer, S., May, R.M., Shaw, G.M. & Nowak, M.A. Virus dynamics and drug treatment. Proc. Natl. Acad. Sci. USA 94, 6971-76 (1997).
34. Perelson, A.S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
35. Baba, M. et al. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of HIV in vitro. Proc. Natl. Acad. Sci. USA 85, 6132-36 (1988).
36. Mitsuya, H. et al. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240, 646-48 (1988).
37. Flexner, C. et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in HIV infection. Antimicrob. Agents Chemother. 35, 2544-50 (1991).
38. Fisher, R.A. et al. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 331, 76-78 (1998).
39. Schooley, R.T. et al. Recombinant soluble CD4 therapy in patients with AIDS and AIDS-related complex. Ann. Intern. Med. 112, 247-53 (1990).
40. Meng, T.C. et al. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 152-160 (1995).
41. Shacker, T. et al. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9145-152 (1995).
42. Chen, J.D., Bai, X., Yang, A.G., Cong, Y. & Chen, S.Y. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nature Med. 3, 1110-1116 (1997).
43. Donzella, G.A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 4, 72-77 (1998).
44. Zinman, B., Tildesley, H., Chiasson, J.L., Tsui, E. & Strack, T. Insulin Lispro in CSII: results of a double-blind crossover study. Diabetes 46, 44043 (1997).
45. Pachl, C. et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 446-54 (1995).
46. Cao, Y. et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retroviruses 11, 353-61 (1995).
47. Schockmel, G.A., Yerly, S. & Perrin, L. Detection of low HIV-1 levels in plasma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14, 179-83 (1997).
48. SAS/STAT User's Guide Version 6, 4th edn., Vol. 1 & 2 (SAS Institute, Cary, North Carolina, 1989).
49. Chan, D. C. and Kim P. S. HIV Entry and Its Inhibition. Cell 93, 681-84 (1998).